首页 | 本学科首页   官方微博 | 高级检索  
检索        

孟鲁司特联合布地奈德雾化吸入用于肺炎支原体感染后慢性咳嗽患儿的效果观察
引用本文:曾穗茹,王蓉梅.孟鲁司特联合布地奈德雾化吸入用于肺炎支原体感染后慢性咳嗽患儿的效果观察[J].医学信息,2018,0(19):137-138,141.
作者姓名:曾穗茹  王蓉梅
作者单位:乌鲁木齐市第一人民医院呼吸科,新疆 乌鲁木齐 830011
摘    要:目的 探讨孟鲁司特联合布地奈德雾化吸入对肺炎支原体感染后慢性咳嗽患儿降钙素原及炎性因子水平的影响。方法选择2016年1月~2018年6月我院收治的肺炎支原体感染后慢性咳嗽患儿106例,按随机数表法分为两组,各53例。对照组给予布地奈德雾化吸入治疗,观察组在此基础上给予孟鲁司特治疗。比较两组治疗后临床疗效、降钙素原水平及炎性因子水平。结果 治疗2个月后,观察组总有效率为94.34%,高于对照组的79.25%,差异有统计学意义(P<0.05);治疗2个月后,观察组患儿PCT为(0.45±0.28)μg/L,白介素6(IL-6)为(16.12±5.87) pg/ml,C反应蛋白(CRP)为(7.86±1.59) mg/L。低于对照组(0.68±0.33) μg/L、(29.62±6.05) pg/ml、(12.31±3.25) mg/L,差异有统计学意义(P<0.05)。结论 孟鲁司特联合布地奈德雾化吸入治疗肺炎支原体感染后慢性咳嗽,可提高临床疗效,降低降钙素原及炎性因子水平。

关 键 词:肺炎支原体感染  慢性咳嗽  孟鲁司特  布地奈德  炎性因子

Efficacy of Montelukast Combined with Budesonide Aerosol Inhalation in Children with Chronic Cough after Mycoplasma Pneumoniae Infection
ZENG Sui-ru,WANG Rong-mei.Efficacy of Montelukast Combined with Budesonide Aerosol Inhalation in Children with Chronic Cough after Mycoplasma Pneumoniae Infection[J].Medical Information,2018,0(19):137-138,141.
Authors:ZENG Sui-ru  WANG Rong-mei
Institution:Department of Respiratory,the First People’s Hospital of Urumqi,Urumqi 830011,Xinjiang,China
Abstract:Objective To investigate the effect of montelukast combined with budesonide aerosol inhalation on the levels of procalcitonin and inflammatory factors in children with chronic cough after mycoplasma pneumoniae infection.Methods 106 children with chronic cough after infection with Mycoplasma pneumoniae from January 2016 to June 2018 were enrolled in our hospital.They were divided into two groups according to the random number table method,53 cases each.The control group was treated with budesonide aerosol inhalation and the observation group with montelukast on this basis.The clinical effect,procalcitonin level and inflammatory factor level were compared between the two groups.Results After 2 months of treatment,the total effective rate of the observation group was 94.34%,which was higher than that of the control group 79.25%,the difference was statistically significant (P<0.05).After 2 months of treatment,the PCT of the observation group was(0.45±0.28) μg/L,interleukin 6(IL-6)was(16.12±5.87) pg/ml,and C-reactive protein (CRP)was(7.86±1.59) mg/L,lower than the control group(0.68±0.33) μg/ L,(29.62 ±6.05) pg/ml,(12.31±3.25) mg/L,the difference was statistically significant(P<0.05). Conclusion Montelukast combined with budesonide aerosol inhalation in the treatment of chronic cough after mycoplasma pneumoniae infection can improve the clinical efficacy and reduce the level of procalcitonin and inflammatory factors.
Keywords:Mycoplasma pneumoniae infection  Chronic cough  Montelukast  Budesonide  Inflammatory factors
点击此处可从《医学信息》浏览原始摘要信息
点击此处可从《医学信息》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号